Posts tagged ‘lymphoma’
When it comes to research into the treatment of hematologic cancers, City of Hope scientists stand out. One study that they presented this week at the annual meeting of the American Society of Hematology suggests a new standard of care for HIV-associated lymphoma, another offers promise for the treatment of relapsing or treatment-resistant lymphoma, and still another points to more effective treatment for acute lymphoblastic leukemia.
Researchers from the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope shared their findings at the annual ASH meeting, held Dec. 6 through 9, in San Francisco. More than 20,000 hematology professionals attended the annual conference, which highlights the hottest topics in the field.
Here are some of the highlights: » Continue Reading
Patients with HIV-associated lymphoma may soon have increased access to the current standard of care for some non-HIV infected patients – autologous stem cell transplants.
Impressive new data, presented Monday at the annual meeting of the American Society of Hematology (ASH) in San Francisco, indicate that HIV-associated lymphoma patients who meet standard eligibility criteria for transplants of their own stem cells respond well to the treatment, even in centers that do not have HIV-specific expertise. HIV infection has historically been viewed as reason to rule out autologous stem cell transplant – the standard of care for non-infected patients with relapsed or treatment-resistant lymphoma – due to their compromised immune system.
The new study could change that perception. It was led by Joseph Alvarnas, M.D., director of Medical Quality and Quality, Risk and Regulatory Management and a physician investigator at the Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope, and colleagues at Johns Hopkins Hospital. The study builds on previous research at City of Hope, including a crucial 2001 publication that was among the first internationally to show these transplants were possible for HIV patients. » Continue Reading
The body’s immune system is usually adept at attacking outside invaders such as bacteria and viruses. But because cancer originates from the body’s own cells, the immune system can fail to see it as foreign. As a result, the body’s most powerful ally can remain largely idle against cancer as the disease progresses. Immunotherapy in general seeks to spur the immune system to action, helping the body fight cancer. One type of immunotherapy —T cell therapy — reprograms immune cells known as T cells to recognize and destroy cancer cells.
A wave of clinical trials
Normally, T cells attack bacteria and other infectious agents. In T cell therapy, T cells are isolated from a sample of the patient’s blood, then genetically engineered to seek out and attack a specific cancer. Researchers grow millions of these engineered T cells in the laboratory. The engineered cells are reinfused into the patient, where they go to work eliminating cancer.
Stephen J. Forman, M.D., the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, has long pursued breakthrough treatments for hematologic cancers and blood-related disorders, and heads up City of Hope’s bone marrow transplant program. Under his direction, a wave of T cell clinical trials is underway, all of which are moving the treatment out of the lab and directly to patients. » Continue Reading
Identifying cures for currently incurable diseases and providing patients with safe, fast and potentially lifesaving treatments is the focus of City of Hope’s new Alpha Clinic for Cell Therapy and Innovation (ACT-I).
The clinic is funded by an $8 million, five-year grant from the California Institute for Regenerative Medicine. The award is part of CIRM’s Alpha Stem Cell Clinics program, which aims to create one-stop centers for clinical trials focused on stem cell treatments for diseases.
Two trials were identified to launch the center, but additional trials are currently enrolling patients and will be part of this clinic. The first trials center on transplants of blood stem cells that have been modified to treat patients with AIDS and lymphoma, and on the use of neural stem cells – which naturally home to cancer cells – to deliver drugs directly to cancers hiding in the brain. Coming soon will be trials that use T cell immunotherapy, developed by researchers in City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute.
“We are committed to finding cures and treatments to diseases that are, for now, incurable,” said John Zaia, M.D., the Aaron D. Miller and Edith Miller Chair in Gene Therapy, chair of the Department of Virology and principal investigator for the stem cell clinic. “This grant recognizes City of Hope’s commitment to and leadership in this endeavor, as well as enables us to pursue the crucially important work of bringing the promising potential of stem cell treatments to fruition.” » Continue Reading
Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on treating people with lymphoma, leukemia and myeloma, as well as other serious blood and bone marrow diseases.
Through this institute, laboratory and physician investigators will expand their work and develop new therapies and possible cures for leukemia, lymphoma and multiple myeloma. The Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope is built upon a foundation that was created by City of Hope’s Stephen J. Forman, M.D., the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at City of Hope, and the leader of the institution’s Hematologic Malignancies Program, and Steven T. Rosen, M.D., the provost and chief scientific officer at City of Hope.
Both are known worldwide for the vision, discipline and compassion with which they approach some of the most complex and difficult diseases that afflict men, women and children. Both are committed to continuing to make scientific breakthroughs while caring for patients in the uniquely patient-centered environment for which City of Hope is known.
“Over the years we have seen the development of therapies that, had we known then what we know now, could have saved more lives. The institute will create a collaborative culture of research and individualized care that will accelerate our research breakthroughs for the patients and families who come to us for help,” Forman said. » Continue Reading
Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a small number of people, the disease may progress to the lymph nodes or internal organs, causing serious complications.
Here Jasmine Zain, M.D., associate clinical professor and director of City of Hope’s T Cell Lymphoma Program, discusses how in recent years, greater research efforts, advanced treatment options and more collaboration among physicians have contributed to better care and outcomes for patients, and helped many to return to a normal life.
What is cutaneous T cell lymphoma (CTCL) and what are the symptoms?
CTCL is a rare form of lymphoma that arises primarily in the skin. It is not to be confused with the more common forms of skin cancer that include melanoma and squamous cell carcinoma. Lymphomas are cancers of the lymphoid system and usually arise in lymph nodes. However, with skin being the largest lymphoid organ in the body and our first line of defense against the outside environment, occasionally it becomes the site of lymphoma formation. » Continue Reading
Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat.
Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in children. In 2014, nearly 1,400 children under the age of 15 are expected to die from cancer in the United States and about 10,450 children will be diagnosed with some form of cancer.
Although there are no widely recommended screening tests for childhood cancers, many cancers can be found early. That’s why it’s important to be aware of the signs and symptoms for some of the most common childhood cancers, including acute lymphoblastic leukemia, lymphoma, brain tumors, neuroblastoma and Wilm’s tumor. » Continue Reading
Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is very taxing on the body, and certain patients — such as those who are older — cannot tolerate the toxicity associated with the process.
But at City of Hope, this does not rule them out of a potentially curative transplant, thanks to our care team’s specialization in nonmyeloablative transplants (also known as a reduced intensity, or “mini,” transplant.)
What is a nonmyeloablative stem cell transplant and how does it work to treat cancer?
Nonmyeloablative stem cell transplant is a way of doing a transplant that is not as intensive as traditional transplant regimens. It uses lower doses of drugs than a standard transplant but still enables us to engraft stem cells from a donor. It then works through utilizing the donor stem cells, which builds an immune reaction against the residual cancer cells — hopefully eliminating the disease and preventing it from returning.
Because it is less intensive, nonmyeloablative transplants are generally used for patients who are older or otherwise too frail to tolerate a traditional transplant, and this procedure has allowed us to perform curative transplants in a greater range of people. » Continue Reading
Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future.
Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approach for cancer treatment, and while the science is quickly advancing, the idea isn’t exactly new.
In the late 1800s – before much was known about the immune system – William Coley, M.D., a New York surgeon, noticed that getting an infection after surgery actually helped some cancer patients. So he began infecting them with certain bacteria, with positive results.
Today, doctors continue to seek ways to harness the immune system to fight disease. City of Hope researchers are examining immunotherapy techniques to treat some of the toughest cancers including gliomas, ovarian cancer and hematologic cancers. One especially promising approach is called adoptive T cell therapy.
Nearly four decades ago, City of Hope began its bone marrow transplant program. Its first transplant reunion celebration was a single patient and his donor, also his brother.
This year, City of Hope welcomed hundreds of hematopoietic cell transplant (HCT) recipients to the annual bone marrow transplant/HCT reunion. Since the program’s inception, City of Hope has performed more than 12,000 hematopoietic cell transplants, for patients ranging in age from less than 1 year old to more than 79 years old.
The reunion of bone marrow transplant patients, one of the highlights of the year for City of Hope, underscores the close relationships that City of Hope caregivers have with their patients, even those who have been free of their cancer for decades. The outcomes for the program underscore the importance of those relationships and the high level of expertise provided here: They are among the very best in the nation. » Continue Reading